Bio + Health

Where Will AI Have the Biggest Impact? Healthcare.

Daisy Wolf and Vijay Pande Posted August 2, 2023

Recently, we received an email about a healthcare panel entitled “Using AI with Modern Fax Capabilities to Reduce Administrative Burden.”

We immediately thought, “wait, what?”

But yes, we had read it correctly: There was a panel on integrating AI with fax machines in healthcare!

Are we stuck in the 1980s? Shouldn’t healthcare just get with the times and stop using fax machines?

We had to laugh.

But under the surface, this email tells us a lot.

It reveals why AI will have a bigger impact in healthcare than in any other industry and why AI talent should be incredibly excited by that opportunity.

Hear us out.

It’s no secret that traditional enterprise software has struggled to penetrate healthcare. Emails about “modern fax capabilities” demonstrate this pretty clearly. Healthcare is 20% of the American economy, but only one of the largest 100 public software companies is a healthcare company.

The successful healthcare software companies are incredible businesses, but they are few and far between. Healthcare as an industry has been slow to adopt technology, reluctant to burden overwhelmed IT teams, and train burned-out staff on new systems.

But that is about to change.

Just as emerging markets went straight from using cash to mobile payments (“leapfrogging” credit cards altogether), healthcare is going to move straight from fax machines to AI (“leapfrogging” traditional vertical software).

With AI, healthtech companies no longer need to fight the uphill battle of training people on software. Instead, they can sell AI that acts like a person and takes more and more of the work off healthcare professionals’ plates, enabling them to work on more interesting problems and practice at the top of their licenses.

The pitch is simple: “Don’t want more software? Cool, we can give you AI ‘people’ who are cheap, fast, cheerful and empathic.”

We believe that any new technology has to be 10 times better to successfully displace the last one—marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.

We believe that any new technology has to be 10 times better to successfully displace the last one—marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.

This revolution will start with the non-clinical use cases. AI will take on the work of call centers, scheduling, prior authorization, medical coding, revenue cycle management, and fighting medical bills.

But the clinical revolution is not far behind. AI can already pass the medical licensing exam to become a doctor and read an x-ray as well as a radiologist. Soon, AI’s accuracy in diagnosing medical issues and recommending treatment plans will surpass humans. Every doctor will have an AI copilot assisting them. Regulatory pathways already exist to bring clinical AI to market, and we’re encouraged by early signals of partnership by lawmakers and regulators.

And this is incredibly exciting for every person on the planet.

The biggest challenges in healthcare are (1) access—there aren’t enough enough good doctors to provide timely care to all who need it (and clinicians are leaving the field in droves due to burn out), and (2) cost—the cost of healthcare has skyrocketed, largely because of increasing labor costs.

AI will solve both of these issues.

When it comes to access, people won’t have to wait months to get quality care. As AI improves, every single person will have a world-class AI doctor in their pocket, spanning all medical specialities. Diagnoses will come months earlier, allowing expedited, AI-guided interventions by doctors who focus their time in more impactful ways.

When it comes to cost, AI will radically decrease spend by shifting care from all-human services to AI-augmented services. Note this is not true in industries that are already software driven—AI is more expensive than enterprise SaaS. But it’s way less expensive than human services, and healthcare is a $4 trillion industry that is mainly human services. AI will help us achieve a future where every person can afford world-class medical care, and medical debt is no longer the number one cause of bankruptcy.

Over the past few decades, almost every major industry has been majorly upleveled by technology. Healthcare is the biggest prize that remains. We know the AI hype cycle has hit healthcare before, but we’re excited by today’s overlap of data availability, public foundation models, and widespread interest. And as we’ve said before, most impactful companies are built at the frontier, and healthcare is the next frontier.

So to any skeptics doubting that AI will have the biggest impact in healthcare, here’s what we have to say:

Find us another industry where AI can solve the industry’s two biggest challenges and save countless lives along the way. We’ll wait.

In the meantime, we’ll be investing in the future so we can tell our grandchildren stories about the panels on fax machines back in our day.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Bio + Health

Infinite Healthcare: What’s It Worth?

Jay Rughani, Jane Rhee, and Julie Yoo
Enterprise

Can AI Help Save Lives?

Kimberly Tan and Michael Chime

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.